The recalled products were sold across 32 states — including Massachusetts, Connecticut, Rhode Island and Vermont.

Nasal spray is being recalled over microbial failure. The U.S. Food and Drug Administration shared information about the recall affecting NeilMed Pharmaceuticals’ NasoGel Spray, last week.

If you suffer from allergies or sinus congestion, you might want to think twice before using this nasal spray. The U.S. Food and Drug Administration is recalling 89,312 bottles of NasoGel nasal ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Ocean Spray is challenging Australians to rethink how they elevate their every day with the launch of its bold and interactive campaign, Is There Anything PURE Can’t Improve? Designed to spark ...

Ocean Spray continues to dominate as the #1 Zero Sugar juice drink brand in the shelf-stable category and the only brand in the category with no artificial sweeteners* The Tropical Punch flavor ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...